Hyperbaric Chamber for Neurological Conditions: Brain Recovery & Research

HBOT is FDA-cleared for two neurological conditions: carbon monoxide poisoning and decompression sickness. Beyond those, a 2025 meta-analysis of 250 TBI patients found significant improvements in memory, attention, and processing speed, and retrospective data from 162 stroke patients showed cognitive improvement in 86% of cases. All other neurological uses remain off-label, but the research base is growing fast. It is one of several neurological applications of hyperbaric oxygen therapy currently being explored in clinical research.

Why the Brain Responds to Hyperbaric Oxygen

Normal atmospheric air contains about 21 percent oxygen at sea level. In a hyperbaric chamber pressurized to 2.0 ATA (atmospheres absolute) breathing 100 percent medical-grade oxygen, the partial pressure of oxygen in the blood and tissues increases dramatically, reaching levels roughly 10 to 15 times higher than normal. This matters for neurological conditions for several reasons.

Brain tissue that has been injured but is not yet dead often exists in a state of ischemic penumbra: alive, but barely, due to compromised blood flow and oxygen delivery. HBOT can reach this tissue through plasma-dissolved oxygen, bypassing damaged or insufficient vascular pathways.

Beyond immediate oxygenation, a 2024 comprehensive review in Frontiers in Neurology identified four key neurobiological mechanisms through which HBOT promotes brain recovery⁶:

• Mitochondrial biogenesis – increased Bcl-2, reduced Bax, enhanced ATP production
• Neurogenesis – upregulation of Wnt-3 and VEGF/ERK signaling pathways
• Synaptogenesis – elevated GAP43 and synaptophysin, supporting new neural connections
• Anti-inflammatory effects – reduced TNF-alpha and IL-6, dampening chronic neuroinflammation

The HBOT research overview covers these mechanisms in more detail across multiple conditions.

HBOT promotes neuroplasticity through four key mechanisms: mitochondrial biogenesis, neurogenesis via VEGF/ERK signaling, synaptogenesis through GAP43 upregulation, and anti-inflammatory effects via TNF-alpha and IL-6 reduction.”
Bin-Alamer et al., 2024, Frontiers in Neurology

What Does the Research Say?

Carbon Monoxide Poisoning

This is HBOT’s clearest neurological success story. Carbon monoxide binds to hemoglobin with far greater affinity than oxygen, and the neurological consequences of severe poisoning, including confusion, cognitive impairment, and delayed neurological syndrome, can be devastating. HBOT dramatically accelerates CO elimination and reduces the incidence of delayed neurological effects. It is one of the 14 FDA-cleared indications and standard of care at centers with hyperbaric facilities.

Decompression Sickness with Neurological Involvement

When nitrogen bubbles form in tissue or blood during or after diving, they can lodge in the spinal cord or brain. HBOT is the definitive treatment, reducing bubble size and restoring perfusion. This is another FDA-cleared indication with strong consensus support.

Traumatic Brain Injury

TBI is one of the most actively studied neurological applications for HBOT. The pathophysiology of TBI includes initial mechanical injury followed by secondary injury cascades: inflammation, oxidative stress, mitochondrial dysfunction, and cell death in surrounding tissue. HBOT targets several of these secondary mechanisms.

A 2016 meta-analysis of 8 studies found that HBOT significantly improved Glasgow Coma Scale scores in TBI patients (pooled difference 3.13, 95% CI 2.34-3.92, P<0.001), with corresponding improvements in Glasgow Outcome Scale scores and lower mortality¹.

More recently, a 2025 meta-analysis of 4 studies involving 250 patients found HBOT significantly improved multiple cognitive domains compared to controls²:

• Memory: mean difference 10.13 (P<0.00001)
• Attention: mean difference 7.99 (P<0.00001)
• Executive function: mean difference 7.16 (P=0.002)
• Information processing speed: mean difference 7.48 (P=0.01)
• Motor skills: mean difference 5.19 (P<0.00001)

In the largest published cohort of 154 chronic TBI patients treated with HBOT (mean 4.6 years post-injury), all cognitive domains improved significantly, with global cognitive scores increasing by 4.6 points (p<0.00001). SPECT imaging confirmed corresponding increases in brain metabolic activity."
Hadanny et al., 2018, BMJ Open

The largest retrospective study followed 154 patients with chronic TBI (average 4.6 years post-injury) through HBOT treatment. All cognitive domains improved significantly, with the largest gains in memory (8.1 points) and attention (6.8 points). SPECT brain imaging confirmed increased metabolic activity in the anterior cingulate, prefrontal, and temporal regions³.

The Military Study Paradox

Four randomized trials on military personnel consistently found HBOT no more effective than sham for post-concussion symptoms. In 2018, the Department of Defense issued a memorandum stating HBOT should not be prescribed for persistent post-concussion symptoms.

These studies contain a critical nuance: the sham treatments used pressurized air at 1.2-1.3 ATA, which may itself have therapeutic effects. When both the treatment and sham groups improved equally, it raised the possibility that pressure itself, rather than 100% oxygen specifically, contributes to neurological recovery. This “sham problem” remains the biggest challenge in HBOT neurological research⁴.

The HBOT and brain injury page covers the TBI-specific evidence in detail. The TBI clinical data page breaks down the numbers. For veterans specifically, who often have overlapping TBI and PTSD, see the veterans and HBOT article.

Stroke Recovery

Stroke is one of the most actively studied neurological applications for HBOT, with evidence varying by timing and stroke type.

Acute Stroke

In the acute phase (hours after stroke onset), HBOT has shown some benefit in small studies by protecting the ischemic penumbra while thrombolysis or thrombectomy is performed. HBOT has not been established as a standard adjunct to acute stroke care, partly because coordinating it with emergency reperfusion therapy is logistically challenging.

Chronic Stroke Recovery

The strongest data comes from a retrospective analysis of 162 post-stroke patients treated with 40-60 daily HBOT sessions at 2 ATA. The results were striking: 86% of patients achieved clinically significant cognitive improvement (defined as >0.5 standard deviation), with benefits observed regardless of stroke type, location, or hemisphere affected. Only baseline cognitive function predicted improvement, meaning even patients years after their stroke responded to treatment⁵.

A retrospective analysis of 162 post-stroke patients found that HBOT improved cognitive function in 86% of cases, with benefits observed regardless of stroke type, location, or side. Only baseline cognitive function predicted improvement.”
Hadanny et al., 2020, Restorative Neurology and Neuroscience

These results are encouraging, but they come from retrospective studies without control groups. The field awaits larger, randomized, multi-center trials before HBOT becomes a standard stroke rehabilitation tool. The full picture for HBOT and stroke recovery covers this research in depth, and the stroke recovery statistics page has the detailed outcome data.

Neurodegenerative Diseases

Parkinson’s Disease

Parkinson’s disease involves progressive loss of dopaminergic neurons in the substantia nigra, driven in part by oxidative stress and mitochondrial dysfunction. HBOT’s anti-inflammatory and mitochondrial-supporting properties make it theoretically interesting, and early animal studies have shown some neuroprotective effects. Human clinical trials are small and preliminary. The Parkinson’s and HBOT article reviews what’s currently known.

Alzheimer’s Disease and Dementia

A 2022 review in GeroScience noted that by 2040, neurodegenerative diseases will be the second leading cause of death in developed countries, and that HBOT has shown promising preclinical effects through reduced neuroinflammation, oxidative stress modulation, and enhanced autophagy⁸. No clinical trials have demonstrated that HBOT effectively treats Alzheimer’s or other dementias in humans. Animal models are not reliably translatable to human neurodegenerative disease.

The Alzheimer’s and HBOT and dementia and HBOT articles cover the current evidence. The cognitive health and HBOT page provides a broader view.

Multiple Sclerosis

MS was one of the earliest neurological conditions studied with HBOT, dating back to the 1980s. Early results generated enthusiasm, but larger controlled trials produced inconsistent results. A Cochrane review concluded that available evidence does not support routine use of HBOT in MS, though some patients report subjective improvements in fatigue and bladder function. HBOT is not a standard MS treatment.

Other Neurological Applications

Post-COVID Neurological Symptoms

Long COVID has emerged as a significant neurological challenge, with brain fog, cognitive dysfunction, and fatigue affecting millions of patients. A 2022 randomized controlled trial by Zilberman-Itskovich et al. found improvements in cognitive function, energy, and quality of life in post-COVID patients treated with HBOT, published in Scientific Reports. A 2024 follow-up study by Catalogna et al. confirmed the durability of these improvements. This is a rapidly evolving area. See the long COVID and HBOT article and long COVID clinical data for the full evidence.

Cerebral Palsy

HBOT for cerebral palsy is one of the more controversial applications. Parents naturally seek every possible intervention for children with CP, and HBOT has been marketed aggressively in some wellness contexts. The clinical evidence is not strong. The Cochrane database and most pediatric neurology guidelines do not support HBOT as an effective treatment for CP. The cerebral palsy and HBOT article gives a full, balanced treatment of the evidence.

What to Expect from HBOT for Neurological Conditions

Neurological HBOT protocols typically run 40 to 60 sessions at pressures between 1.5 and 2.0 ATA, often lower than protocols used for wound healing or radiation injury. Sessions run 60 to 90 minutes. Improvement, when it occurs, is often gradual and may not be fully apparent until weeks after completing the course.

Clinical guidelines from Hadanny et al. (2023) recommend patient selection using standardized cognitive tests combined with functional brain imaging, with Type 2a recommendation and Level A evidence for acute moderate-severe TBI, and Level B-R evidence for chronic mild TBI in patients with metabolic dysfunction visible on neuroimaging⁴.

The what to expect guide explains the logistics of treatment. The before and after results page shows what patient outcomes tend to look like.

Is HBOT Right for Your Neurological Condition?

The honest answer is that it depends strongly on your specific condition, the severity and duration of your symptoms, and what other treatments you’ve tried. For FDA-cleared neurological indications (CO poisoning, decompression sickness), HBOT is standard of care. For stroke, TBI, and other acquired brain injuries, the evidence supports careful consideration with appropriate expectations. For degenerative diseases and off-label applications, the research is more preliminary.

A board-certified hyperbaric physician can evaluate whether your situation is likely to benefit from treatment and help you weigh it against the time and cost commitment involved. The cost guide and insurance coverage information will help you understand the financial picture.

How Do You Find the Right HBOT Clinic?

Neurological HBOT applications are more nuanced than wound healing, and not all hyperbaric facilities are equally equipped. Hospital-based programs affiliated with neurology departments or rehabilitation medicine are generally better positioned than standalone wellness-oriented centers. Neurological patients may require baseline and post-treatment cognitive assessments, coordination with neurologists adjusting medications, and expertise in managing conditions like seizure disorders or autonomic dysfunction during sessions.

When evaluating facilities, ask whether they have experience treating your specific condition, whether they coordinate with your existing neurological care team, and what outcome assessments they use.

Combining HBOT with Rehabilitation

For acquired neurological conditions (stroke, TBI, post-COVID), HBOT is most compelling when integrated with active rehabilitation. The mechanisms that HBOT stimulates, including neuroplasticity, angiogenesis, and BDNF production, build the biological substrate for functional recovery. Rehabilitation (physical therapy, occupational therapy, speech-language therapy, cognitive rehabilitation) provides the activity-dependent stimulation that shapes how that substrate gets organized. Most neurological recovery specialists recommend concurrent rehabilitation rather than choosing one over the other.

References

1. Wang F, Wang Y, Sun T, Yu HL. “Hyperbaric oxygen therapy for the treatment of traumatic brain injury: a meta-analysis.” Neurological Sciences, 2016;37(5):693-701. DOI: 10.1007/s10072-015-2460-2
2. Shahid S, et al. “Hyperbaric oxygen therapy for neurocognitive deficits following traumatic brain injury: systematic review and meta-analysis.” Annals of Medicine and Surgery, 2025. DOI: 10.1097/MS9.0000000000003902
3. Hadanny A, et al. “Effect of hyperbaric oxygen therapy on chronic neurocognitive deficits of post-TBI patients.” BMJ Open, 2018;8(9):e023387. DOI: 10.1136/bmjopen-2018-023387
4. Hadanny A, et al. “The efficacy of hyperbaric oxygen therapy in TBI patients: literature review and clinical guidelines.” Medical Research Archives, 2023;11(7). DOI: 10.18103/mra.v11i7.2.4161
5. Hadanny A, et al. “Hyperbaric oxygen therapy improves neurocognitive functions of post-stroke patients.” Restorative Neurology and Neuroscience, 2020;38(1):93-105. DOI: 10.3233/RNN-190959
6. Bin-Alamer O, et al. “Hyperbaric oxygen therapy as a neuromodulatory technique: a review of the recent evidence.” Frontiers in Neurology, 2024;15:1450134. DOI: 10.3389/fneur.2024.1450134
7. Marcinkowska A, et al. “Impact of hyperbaric oxygen therapy on cognitive functions: a systematic review.” Neuropsychology Review, 2021;31(3):462-486. DOI: 10.1007/s11065-021-09500-9
8. Mensah-Kane P, Sumien N. “The potential of hyperbaric oxygen as a therapy for neurodegenerative diseases.” GeroScience, 2022;44(3):1471-1488. DOI: 10.1007/s11357-022-00707-z
9. Biggs AT, et al. “Effect sizes for symptomatic and cognitive improvements in TBI following HBOT.” Journal of Applied Physiology, 2021;130(6):1594-1603. DOI: 10.1152/japplphysiol.01084.2020
10. Tal S, et al. “Hyperbaric oxygen may induce angiogenesis in patients suffering from prolonged post-concussion syndrome due to TBI.” Restorative Neurology and Neuroscience, 2015;33(6):943-951. DOI: 10.3233/RNN-150585

Seph Fontane Pennock

Author

Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.

Website